Nemirostad (Nebivolol)

Nebivolol blocks β1‑adrenergic receptors in the heart, which slows heart rate and reduces contractile force. At the same time it stimulates nitric oxide release from the endothelium, causing blood vessels to relax. This dual action lowers blood pressure and eases the workload on a failing heart.

The appropriate dose of Nemirostad is determined by a qualified prescriber based on the individual’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments may be needed for renal impairment or other special populations.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by the treating physician.

To request Nemirostad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is distinguished by its additional nitric‑oxide‑mediated vasodilatory effect, which can result in fewer metabolic side effects compared with non‑vasodilating beta blockers. It is often chosen for patients who need blood‑pressure control with a lower risk of adverse lipid or glucose changes.

Nemirostad tablets should be stored at room temperature, below 25 °C, in the original container. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

Nemirostad is taken orally, usually once daily, with or without food as directed by the prescribing clinician. Patients should follow the exact timing and dosage instructions provided on the prescription label.

Serious risks include severe bradycardia, heart block, acute hypotension, bronchospasm in susceptible individuals, and rare cases of hepatic dysfunction or cardiogenic shock. Patients should seek immediate medical attention if they experience fainting, severe shortness of breath, or signs of an allergic reaction.

Nemirostad is contraindicated in patients with known hypersensitivity to nebivolol, those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and individuals with uncompensated heart failure. Caution is also advised for patients with severe asthma or chronic obstructive pulmonary disease.